Kalderos
We're Hiring!
Kalderos Company Growth, Stability & Outlook
What People Are Saying About Kalderos
-
Investor Backing & Capital Strength: Recent funding trackers indicate a fresh 2025 round of about $26.35M, bringing total capital raised to roughly $76M—providing fuel to scale product and go‑to‑market.
-
Market Expansion: Multiple 2025–2026 manufacturer and distributor notices show transitions to Truzo (e.g., Alkermes, Organon, Gilead via Cencora). These migrations suggest growing adoption across stakeholders.
-
Product Line Growth: Kalderos promotes Truzo as an end‑to‑end drug discount management platform and continues to enhance solutions like Discount Hub and Commercial Discount Monitoring. Industry commentary and company materials highlight expanding capabilities aligned to today’s 340B environment.
